Dr Tarun Mamidi

Founder & CEO

What’s driving the remarkable transformation of the global and Indian genomics services land­scape? The plain answer is a combination of technological progress, affordability, and scientific am­bition. Additionally, falling genome sequencing costs and the growing adoption of personalized and precision med­icine are fueling unprecedented demand. Advances in AI and machine learning are making data analysis faster and more cost-effective, while government initiatives such as India’s recent release of 10,000 whole-genome samples are further accelerating this momentum.

As sequencing is becoming affordable and accessible, huge amounts of patient data is being generated and waiting to be analyzed. Each patient generates nearly 100 GB of data, containing around 5 million mutations. While most genetic diseases are caused by mutations in either one or two genes, identifying which mutations out of ~5M still requires manual comparison with patient symptoms and extensive literature review. Even with AI support using current platforms, at least 100 mutations per patient demand close examination to identify the disease-causing mutation. Even then, ~50 percent of patients still remain undiagnosed with a report including mutation of uncertain significance needing further research.

Positioned at the intersection of these opportunities and challenges, Mamidi Health offers a dynamic solution. By combining advanced AI algorithms with customizable workflows, the company addresses the bottlenecks in genomic interpretation, making cutting-edge analysis accessible for both common and rare diseases.

AI-Driven Innovation

Mamidi Health launched in India earlier this year and has quickly expanded to the US, serving hospitals and state universities in both countries. Over the years, the company has built a strong team of AI researchers and experienced bioinformatics scientists, focusing on service expansion and innovation in AI-powered genomic analysis. Notably, its AIVA platform empowers hospitals, diagnostic centers and research labs to efficiently analyze genomic data with AI precision. “For a rare disease patient, diagnosis can often take up to six years due to manual analysis and limited expert availability. Our AI platform and agents make the process faster, affordable, accessible, and accurate, allowing expert-level insights to be available anywhere,” states Dr Tarun Mamidi, Founder & CEO, Mamidi Health.

Not to forget, its flagship platform, AIVA, is an AI-assisted clinical analyst agent that performs end-to-end genomic analysis. Through natural, conversational queries, users can easily explore genomic data and reach diagnosis for patients with both common and rare diseases. Furthermore, AIVA automatically scans relevant literature, utilizes in-house knowledge graphs and identifies key genes and mutations by providing a smooth, intelligent and intuitive analysis experience.

Smart Edge

The Mamidi Health team combines deep domain knowledge with technical excellence. Its experts have firsthand experience with genomic workflows and provide direct, responsive support to clients. The team also publishes tutorials and demo videos regularly which are accessible within the platform for assistance. Clients also get prioritized assistance from developers and even admin through their slack channel. In total, the team’s hands-on expertise ensures challenges are addressed efficiently, driving growth and client satisfaction. With respect to R&D, the company integrates this into its daily operations rather than treating it as a separate function. The team works with top-tier AI models, including OpenAI, Anthropic and Gemini, benchmarking their performance across tasks. “We are proud to be the first in India to introduce conversational-style genomic analysis, turning continuous R&D into real, client-focused innovation”, states Tarun. To note, Gemini excels at generating structured clinical reports, while OpenAI models are strong in tool-calling and literature retrieval.

Client-Centric Approach

After-sales support forms a core part of Mamidi Health’s value model. Since genomic research evolves continuously, analysis is never final. The platform regularly integrates new findings from public databases, enabling users to query updated information and literature anytime. Additionally, the team monitors model performance and maintains a Slack support channel for real-time issue resolution, deploying feature updates within days.

Furthermore, the company aims to make genomic insights accessible to hospitals and diagnostic centers across India, including tier two and tier three cities, bridging the gap with global healthcare standards. Notably, the company has developed its MVP within four months, leveraging AI for accelerated and reliable product development.

Map for the Future

Mamidi Health plans to expand beyond genome data into multi-omic analysis, integrating transcriptomics and proteomics for more accurate diagnostics. In a nutshell, the company is working to make its AI agent fully autonomous. This will make it capable of analyzing samples and generating clinical reports without manual input. Furthermore, API integration with hospital systems is underway, enabling seamless deployment within existing infrastructures. In a nutshell, the company aims to extend its global presence beyond India and the US, strengthening its position as a leader in AI-powered genomics innovation.